ATE510451T1 - Zusammensetzungen mit reifen dendritischen zellen und verfahren zu ihrer kultivierung - Google Patents

Zusammensetzungen mit reifen dendritischen zellen und verfahren zu ihrer kultivierung

Info

Publication number
ATE510451T1
ATE510451T1 AT07755113T AT07755113T ATE510451T1 AT E510451 T1 ATE510451 T1 AT E510451T1 AT 07755113 T AT07755113 T AT 07755113T AT 07755113 T AT07755113 T AT 07755113T AT E510451 T1 ATE510451 T1 AT E510451T1
Authority
AT
Austria
Prior art keywords
dendritic cells
agonist
signaling
methods
receptor
Prior art date
Application number
AT07755113T
Other languages
German (de)
English (en)
Inventor
Irina Tcherepanova
Donald Healey
Atsushi Hinohara
Melissa Adams
Mark Debenedette
Original Assignee
Argos Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Argos Therapeutics Inc filed Critical Argos Therapeutics Inc
Application granted granted Critical
Publication of ATE510451T1 publication Critical patent/ATE510451T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4238—Regulators of development
    • A61K40/424—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4246—Telomerase or [telomerase reverse transcriptase [TERT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/56—Kidney
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/52—CD40, CD40-ligand (CD154)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT07755113T 2006-04-07 2007-04-06 Zusammensetzungen mit reifen dendritischen zellen und verfahren zu ihrer kultivierung ATE510451T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/400,774 US8513008B2 (en) 2004-10-07 2006-04-07 Mature dendritic cell compositions and methods for culturing same
PCT/US2007/008734 WO2007117682A2 (en) 2006-04-07 2007-04-06 Mature dendritic cell compositions and methods for culturing same

Publications (1)

Publication Number Publication Date
ATE510451T1 true ATE510451T1 (de) 2011-06-15

Family

ID=38581685

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07755113T ATE510451T1 (de) 2006-04-07 2007-04-06 Zusammensetzungen mit reifen dendritischen zellen und verfahren zu ihrer kultivierung

Country Status (10)

Country Link
US (4) US8513008B2 (https=)
EP (1) EP2003969B1 (https=)
JP (1) JP5425618B2 (https=)
KR (1) KR101425686B1 (https=)
CN (1) CN101460054B (https=)
AT (1) ATE510451T1 (https=)
AU (1) AU2007235227B2 (https=)
CA (1) CA2648675C (https=)
DK (1) DK2003969T3 (https=)
WO (1) WO2007117682A2 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8513008B2 (en) * 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
WO2006042177A2 (en) * 2004-10-07 2006-04-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
JP5020935B2 (ja) 2005-04-08 2012-09-05 アルゴス セラピューティクス，インコーポレイティド 樹状細胞組成物および方法
PL2066339T3 (pl) * 2006-09-18 2015-02-27 Univ Arkansas Kompozycje i sposoby zwiększania odpowiedzi immunologicznych
US20110086904A1 (en) * 2007-09-17 2011-04-14 The Trustees Of The University Of Pennsylvania GENERATION OF HYPERSTABLE mRNAs
WO2009059018A1 (en) * 2007-10-30 2009-05-07 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
PT3097926T (pt) 2007-11-01 2020-01-08 Univ Guelph Composições e métodos de potenciação das respostas imunitárias frente a eimeria
EP2072617A1 (en) * 2007-12-12 2009-06-24 Trimed Biotech GmbH Method for producing dendritic cells
EP2254998B1 (en) 2008-02-28 2015-12-23 Argos Therapeutics, Inc. Transient expression of immunomodulatory polypeptides for the prevention and treatment of autoimmune disease, allergy and transplant rejection
ES2643646T3 (es) 2010-01-21 2017-11-23 The Board Of Trustees Of The University Of Arkansas Vectores de vacuna y métodos para potenciar las respuestas inmunitarias
MX350306B (es) 2010-06-09 2017-09-04 Univ Arkansas Vacuna y metodos para reducir una infeccion por campylobacter.
EP2621951A1 (en) * 2010-09-29 2013-08-07 Université de Liège Combination of an agonistic anti-cd40 monoclonal antibody or a cd40 ligand and inactivated or attenuated bacteria for use in the treatment and/or prevention of mastitis
DE13746292T1 (de) * 2012-02-10 2014-10-30 Hakushinkouseikai Foundation Proliferationsmittel für monozyten, kulturmedium zur proliferation von monozyten, verfahren zur herstellung von monozyten, verfahren zur herstellung dendritischer zellen und verfahren zur herstellung eines impfstoffs mit dendritischen zellen
AR094791A1 (es) 2013-02-14 2015-08-26 Univ Arkansas Composiciones y métodos para mejorar las respuestas inmunes ante una infección por eimeria o para limitar una infección por eimeria
AU2014239557B2 (en) 2013-03-15 2019-01-03 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
WO2015127190A1 (en) * 2014-02-21 2015-08-27 Argos Therapeutics, Inc. Tscm cells and methods for use
US9730989B2 (en) 2015-07-02 2017-08-15 PrimeVax Immuno-Oncology, Inc. Compositions and methods for combination therapy with dengue virus and dendritic cells
CA2999881A1 (en) * 2015-09-26 2017-03-30 PrimeVax Immuno-Oncology, Inc. Compositions and methods for producing dendritic cells
WO2017102010A1 (en) * 2015-12-17 2017-06-22 Biontech Rna Pharmaceuticals Gmbh Novel cytokine fusion proteins
CN109104870B (zh) * 2016-01-15 2021-10-15 丁恩雨 一种能够增强mRNA稳定性和可译性的通用核酸药物载体
KR102767638B1 (ko) 2016-05-03 2025-02-20 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 면역자극 및 항원 폴리펩티드를 포함하는 효모 백신 벡터, 및 그를 이용하는 방법
JP2020500847A (ja) 2016-11-16 2020-01-16 プライムヴァックス イミュノ−オンコロジー，インク． 癌の処置のための併用免疫療法
EP3565567A4 (en) 2017-01-04 2020-07-29 Primevax Immuno-Oncology, Inc. COMPOSITIONS AND METHODS OF THERAPY WITH DENGUE VIRUS
JP2021502419A (ja) 2017-11-07 2021-01-28 コイミューン インコーポレイテッド 樹状細胞治療のための方法および使用
CN111166876B (zh) * 2018-11-13 2022-10-11 北京启辰生生物科技有限公司 一种免疫增强剂组合和编码核酸及其应用
KR102698871B1 (ko) * 2021-09-10 2024-08-28 이종균 수지상 세포, 자연 살해 세포 및 세포 독성 t 세포를 포함하는 암의 예방 또는 치료용 생물학적 조성물
WO2024231621A1 (fr) * 2023-05-05 2024-11-14 Centre National De La Recherche Scientifique Acide nucleique synthetique et ses utilisations therapeutiques

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0411228B1 (en) 1989-07-31 1995-11-08 International Business Machines Corporation Controlled fiber-optic switch
US5936076A (en) 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5981724A (en) * 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US7405270B2 (en) 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
ES2198025T3 (es) 1991-10-25 2004-01-16 Immunex Corporation Anticuerpos contra cd40-l.
TW261533B (https=) 1992-07-16 1995-11-01 Kirin Brewery
AU683026B2 (en) 1992-10-22 1997-10-30 Kirin Pharma Kabushiki Kaisha Novel shingoglycolipid and use thereof
EP0694558B1 (en) 1993-04-15 1999-01-27 Kirin Beer Kabushiki Kaisha Novel sphingoglycolipid and use thereof
PL181496B1 (pl) * 1996-03-20 2001-07-31 Politechnika Slaska Im Wincent Sposób wytwarzania ß-naftolu PL
EP0961824A4 (en) 1996-07-10 2003-01-29 Immunex Corp METHOD FOR ACTIVATING DENTRITIC CELLS
US6017527A (en) * 1996-07-10 2000-01-25 Immunex Corporation Activated dendritic cells and methods for their activation
TW555562B (en) * 1996-12-27 2003-10-01 Kirin Brewery Method for activation of human antigen-presenting cells, activated human antigen-presenting cells and use thereof
JP3495740B2 (ja) * 1997-04-10 2004-02-09 麒麟麦酒株式会社 α−グリコシルセラミドを含有するＮＫＴ細胞活性化剤
TW575420B (en) * 1997-09-22 2004-02-11 Kirin Brewery Composition for enhancing cellular immunogenicity comprising alpha-glycosylceramides
DE69840739D1 (de) 1997-10-27 2009-05-28 Merix Bioscience Inc Methode und Zusammensetzung zur Herstellung von reifen dendritischen Zellen
DE69940731D1 (de) 1998-05-26 2009-05-28 Genitrix Llc Zusammensetzungen und verfahren zur modulation einer immunantwort auf ein antigen durch verabreichung von zytokine-beladenen zellen
AU5178800A (en) * 1999-06-01 2000-12-18 Cornell Research Foundation Inc. Activation of dendritic cells to enhance immunity
US20030077263A1 (en) * 1999-10-29 2003-04-24 Immunex Corporation Method of activating dendritic cells
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
US20030059427A1 (en) 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
JP5184732B2 (ja) * 2000-06-19 2013-04-17 ベス イスラエル デアコネス メディカル センター Ｔ細胞亜集団に特異的なモノクローナル抗体およびポリクローナル抗体の組成物および使用方法
WO2001098317A2 (en) * 2000-06-22 2001-12-27 The Brigham And Women's Hospital, Inc. Alpha-glycosylceramides for treating bacterial and fungal infections
DE10041515A1 (de) 2000-08-24 2002-03-14 Gerold Schuler Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen
AU2002232447A1 (en) 2000-11-02 2002-05-15 Immunex Corporation Method of enhancing lymphocyte-mediated immune responses
US7405076B2 (en) * 2000-11-14 2008-07-29 Universite Libre De Bruxelles Generation and use of dendritic cells
DE60117167T2 (de) * 2001-01-15 2006-10-05 I.D.M. Immuno-Designed Molecules Verfahren zur herstellung von submikropartikel-suspensionen pharmazeutischer substanzen
US7767202B2 (en) 2001-03-16 2010-08-03 The Johns Hopkins University Modulation of systemic immune responses by transplantation of hematopoietic stem cells transduced with genes encoding antigens and antigen presenting cell regulatory molecules
EP1270732A1 (en) 2001-06-21 2003-01-02 Schuler, Gerold Improved transfection of eukaryontic cells with linear polynucleotides by electroporation
EP1409648A1 (en) * 2001-07-25 2004-04-21 I.D.M. Immuno-Designed Molecules New isolated dendritic cells, a process for preparing the same and their use in pharmaceutical compositions
EP1434859A2 (en) * 2001-07-25 2004-07-07 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
EP1437358B1 (en) 2001-08-16 2006-10-18 Daiichi Asubio Pharma Co., Ltd. Novel glycolipid and remedial agent for autoimmune disease containing the same as active ingredient
EP1444330A1 (en) * 2001-11-07 2004-08-11 Kirin Beer Kabushiki Kaisha Expansion of t cells in vitro and expanded t cell populations
AU2003251518B2 (en) 2002-06-13 2009-07-02 New York University Synthetic C-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases
AU2003295331A1 (en) 2002-09-19 2004-04-23 Centocor, Inc. Method of inducing maturation of dendritic cells and uses therefor
BR0314640A (pt) * 2002-09-20 2005-08-02 Kirin Brewery Inibidor de vìrus de hepatite c compreendendo, como um ingrediente ativo, alfa-glicosilceramida
US20040146948A1 (en) * 2002-10-18 2004-07-29 Centenary Institute Of Cancer Medicine And Cell Biology Compositions and methods for targeting antigen-presenting cells with antibody single-chain variable region fragments
AU2003296439B2 (en) * 2002-12-10 2009-05-07 Argos Therapeutics, Inc. In situ maturation of dendritic cells
SE0301109D0 (sv) 2003-04-14 2003-04-14 Mallen Huang Nucleotide vaccine composition
US20050003533A1 (en) * 2003-05-08 2005-01-06 Pawel Kalinski Mature type-1 polarized dendritic cells with enhanced IL-12 production and methods of serum-free production and use
EP1648555B1 (en) 2003-07-18 2015-09-02 Eastern Virginia Medical School Method for introducing an Agent into a Cell
CA2546378A1 (en) 2003-11-25 2005-06-09 Argos Therapeutics, Inc. Mrna transfected antigen presenting cells
CA2560969A1 (en) * 2004-03-31 2005-11-03 New York University Novel synthetic c-glycolipids, their synthesis and use to treat infections, cancer and autoimmune diseases
US8513008B2 (en) 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
WO2006042177A2 (en) * 2004-10-07 2006-04-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
JP5020935B2 (ja) * 2005-04-08 2012-09-05 アルゴス セラピューティクス，インコーポレイティド 樹状細胞組成物および方法

Also Published As

Publication number Publication date
KR101425686B1 (ko) 2014-08-01
CA2648675A1 (en) 2007-10-18
EP2003969A2 (en) 2008-12-24
KR20090006078A (ko) 2009-01-14
CN101460054B (zh) 2014-03-12
US20070082400A1 (en) 2007-04-12
CA2648675C (en) 2015-03-10
WO2007117682A2 (en) 2007-10-18
US9523077B2 (en) 2016-12-20
EP2003969B1 (en) 2011-05-25
DK2003969T3 (da) 2011-09-12
US20140017788A1 (en) 2014-01-16
JP5425618B2 (ja) 2014-02-26
US20120269832A1 (en) 2012-10-25
WO2007117682A3 (en) 2008-10-16
US20170096639A1 (en) 2017-04-06
US8513008B2 (en) 2013-08-20
EP2003969A4 (en) 2009-05-13
JP2009533025A (ja) 2009-09-17
AU2007235227B2 (en) 2012-10-04
CN101460054A (zh) 2009-06-17
AU2007235227A1 (en) 2007-10-18
US10184108B2 (en) 2019-01-22

Similar Documents

Publication Publication Date Title
ATE510451T1 (de) Zusammensetzungen mit reifen dendritischen zellen und verfahren zu ihrer kultivierung
ATE489455T1 (de) Zusammensetzungen reifer dendritischer zellen und verfahren zu deren kultivierung
JP6788629B2 (ja) 濃縮された腫瘍反応性ｔ細胞集団を腫瘍から作製する方法
Ziegler Thymic stromal lymphopoietin and allergic disease
JP2009533025A5 (https=)
US10731128B2 (en) Compositions and methods for in vitro activation and expansion of serial killer T cell populations and passive immunization of a cancer patient with tumor cell killing cells
MX2010005783A (es) Secuencias de aminoacidos dirigidas contra citoquinas heterodimericas y/o sus receptores y polipeptidos que comprenden las mismas.
BRPI0212545B8 (pt) método ex vivo ou in vitro para produzir uma população de célula dendrítica madura e método para produzir células t
TN2012000138A1 (en) Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same
EP4516896A3 (en) Methods and compositions for preparing genetically engineered cells
JP2019502693A (ja) 新規サイトカイン融合タンパク質
WO2009038760A3 (en) Human gm-csf antigen binding proteins
KR20140083987A (ko) 효모-muc1 면역요법 조성물 및 그 용도
IL187628A (en) Method of culturing human embryonic stem cells into dendritic cells
WO2001077171A3 (en) Soluble zalpha11 cytokine receptors
WO2017100338A4 (en) Improved compositions and methods for viral delivery of neoepitopes and uses thereof
WO2002012345A3 (en) Soluble zcytor 11 cytokine receptors
FI3273986T3 (fi) Uusia peptidejä ja peptidien yhdistelmiä käytettäväksi immunoterapiassa eri syöpiä vastaan
US20160341718A1 (en) Methods for testing t cell priming efficacy in a subject
ATE546464T1 (de) Verfahren zur produktion von rekombinantem protein in cho-zellen
Trepiakas et al. Comparison of α-Type-1 polarizing and standard dendritic cell cytokine cocktail for maturation of therapeutic monocyte-derived dendritic cell preparations from cancer patients
RU2020109423A (ru) Способы и композиции для получения сурфактантного белка d (sp-d)
CN102898528B (zh) 钙网蛋白-可溶性程序性死亡受体1的融合蛋白及其制备方法和用途
KR101270999B1 (ko) 결핵균의 Ｒｖ２２９９ｃ 단백질을 이용한 수지상 세포의 성숙방법
PL2207795T3 (pl) Sposób wytwarzania dojrzałego, rekombinowanego alergenu grupy I roztoczy

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2003969

Country of ref document: EP